Biologic agents in the management of inflammatory eye diseases

Current Allergy and Asthma Reports

Volumn 8, Issue 4, 2008, Pages 339-347

  Michalova, Kira ^b   Lim, Lyndell ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOPLEGIC AGENT; CYCLOSPORIN; DACLIZUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RITUXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ALPHA INTERFERON; ANTIINFLAMMATORY AGENT; CYTOKINE; CYTOKINE RECEPTOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANAPHYLAXIS; ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; B CELL LEUKEMIA; B CELL LYMPHOMA; BEHCET DISEASE; BLOOD PRESSURE FLUCTUATION; CHORIORETINITIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DEPRESSION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE OPHTHALMOPATHY; EYE INFLAMMATION; FATIGUE; FIBROMYALGIA; FLU LIKE SYNDROME; HUMAN; INFECTION; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE SCLEROSIS; PSORIASIS; PSORIATIC ARTHRITIS; RELAPSE; REMISSION; RETINA VASCULITIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SCLERITIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SPONDYLOARTHROPATHY; SYMPATHETIC OPHTHALMIA; THROMBOSIS; TUBERCULOSIS; UVEITIS; VASCULITIS; WEGENER GRANULOMATOSIS; DRUG ANTAGONISM; EYE DISEASE; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; CYTOKINES; EYE DISEASES; HUMANS; INFLAMMATION; INTERFERON-ALPHA; RECEPTORS, CYTOKINE; RECOMBINANT FUSION PROTEINS; SCLERITIS; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS;

EID: 50349090448     PISSN: 15297322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11882-008-0054-2     Document Type: Review

References (60)

1. International Study Group for Behcet's Disease: Criteria for diagnosis of Behçet's disease. Lancet 1990, 335:1078-1080.
2. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al.: Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 2001, 358:295-296.
3. Ohno S, Nakamura S, Hori S, et al.: Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 2004, 31:1362-1368.
4. Sfikakis PP, Kaklamanis PH, Elezoglou A, et al.: Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004, 140:404-406.
5. Tugal-Tutkun I, Mudun A, Urgancioglu M, et al.: Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease. Arthritis Rheum 2005, 52:2478-2484.
6. Mushtaq B, Saeed T, Situnayake RD, Murray PI: Adalimumab for sight threatening uveitis in Behçet's disease. Eye 2007, 21:824-825.
7. van Laar JAM, Missoten T, van Daele PLA, et al.: Adalimumab, a new modality for Behçet's disease? Ann Rheum 2007, 66:565-566.
8. Saurenmann RK, Levin AV, Rose JB, et al.: Tumour necrosis factor α inhibitors in the treatment of childhood uveitis. Rheumatology 2006, 45:982-989.
9. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006, 244:1692-1695.
10. Bodaghi B, Gendron G, Bertrand Wechsler B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: A retrospective monocentric study of 45 patients. Br J Ophthalmol 2007, 91:335-339.
11. Kotter I, Zierhut M, Eckstein AK, et al.: Human recombinant interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003, 87:423-431.
12. Lockwood CM, Hale G, Waldman H, Jayne DRW: Remission induction in Behçet's disease following lymphocyte depletion by the anti-CD 52 antibody CAMPATH 1-H. Rheumatology 2003, 42:1539-1544.
13. Buggage RR, Levy-Clarke G, Sen HN, et al.: A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflam 2007, 15:63-70.
14. Nussenblatt RB, Fortin E, Schiffman R, et al.: Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proc Natl Acad Sci U S A 1999, 96:7462-7466.
15. Papaliodis GN, Chu D, Foster CS: Treatment of ocular inflammatory disorders with daclizumab. Ophthalmology 2003, 110:786-789.
16. Nussenblat RB, Peterson JS, Foster CS, et al.: Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 2005, 112:764-770.
17. Ziegenhagen MW, Rothe ME, Zissel G, Muller-Quernheim J: Exaggerated TNFalpha release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19:185-190.
18. Baughman RP, Drent M, Kavuru M, et al.: Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Resp Crit Care Med 2006, 174:795-802.
19. Doty JD, Mazur JE, Marc A, Judson MA: Treatment of sarcoidosis with infliximab. Chest 2005, 127:1064-1071.
20. Baughman RP, Lower EE, Bradley DA, et al.: Etanercept for refractory ocular sarcoidosis: Results of a double-blind randomized trial. Chest 2005, 128:1062-1147.
21. Callejas-Rubio JL, Ortego-Centeno N, Lopez-Perez L, Benticuaga MN: Treatment of therapy-resistant sarcoidosis with adalimumab. Clin Rheumatol 2006, 25:596-597.
22. Gallagher M, Quinones K, Cervantes-Castaneda RE, et al.: Biological response modifier therapy for refractory childhood uveitis. Br J Ophthalmol 2007, 91:1341-1344.
23. Petty RE, Southwood TR, Baum J, et al.: Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban 1997. J Rheumatol 1998, 25:1991-1994.
24. Carvounis PE, Herman DC, Cha S, Burke JP: Incidence and outcomes of uveitis in juvenile rheumatoid arthritis, a synthesis of the literature. Graefes Arch Clin Exp Ophthalmol 2006, 244:281-290.
25. Reiff A, Takei S, Sadeghi S, et al.: Etanercept therapy in children with treatment-resistant uveitis. Arthritis Rheum 2001, 44:1411-1415.
26. Smith JA, Thompson DJS, Whitcup SM, et al.: A randomized, placebo controlled, double masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 2005, 53:18-23.
27. Quartier P, Taupin P, Bourdeaut F, et al.: Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003, 48:1093-1101.
28. Lovell DJ, Giannini EH, Reiff A, et al.; Pediatric Rheumatology Collaborative Study Group: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000, 342:763-769.
29. Tynjälä P, Lindahl P, Honkanen V, et al.: Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66:548-550.
30. Kahn P, Weis M, Imundo LF, Levy DM: Favorable response to high-dose infliximab for refractory childhood uveitis. Ophthalmology 2006, 113:860-864.
31. Biester S, Deuter C, Michels H, et al.: Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007, 91:319-324.
32. Vazquez-Cobian LB, Flynn T, Lehman TJA: Adalimumab therapy for childhood uveitis. J Pediatr 2006, 149:572-575.
33. Braun J, Sieper J: Biological therapies in the spondyloarthritides - the current state. Rheumatology 2004, 43:1072-1084.
34. Braun J, Baraliakos X, Listing J, Sieper J: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447-2451.
35. El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 2002, 109:2342-2346.
36. Sobrin L, Kim EC, Christen W, et al.: Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007, 125:895-900.
37. Van Rijthoven AW, Jacobs JWV Seronegative spondylarthropathy: variable manifestations, common characteristics. Ned Tijdschr Geneeskd 2007, 151:1377-1381.
38. Taban M, Dupps WJ, Mandel B, Perez V: Etanercept (Enbrel)-associated inflammatory eye disease: Case report and review of the literature. Ocul Immunol Inflamm 2006, 14:145-150.
39. Lim LL, Fraunfelder FW, Rosenbaum JT: Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007, 56:3248-3252.
40. Suhler EB, Smith JR, Wertheim MS, et al.: A prospective trial of infliximab therapy for refractory uveitis. Arch Ophthalmol 2005, 123:903-912.
41. Lindstedt EW, Baarsma GS, Kuijpers RWAM, van Hagen PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005, 89:533-536.
42. Ardoin SP, Kredich D, Rabinovich E, et al.: Infliximab to treat chronic noninfectious uveitis in children: Retrospective case series with long-term follow-up. Am J Ophthalmol 2007, 144:844-849.
43. Foster CS, Tufail F, Waheed NK, et al.: Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol 2003, 121:437-440.
44. Plskova J, Greiner K, Forrester JV: Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007, 144:55-61.
45. Deuter CE, KoeAter I, Guenaydin I, et al.: Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006, 26:786-791.
46. Dick AD, Meyer P, James T, et al.: Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000, 84:107-109.
47. Tappeiner C, Heinz C, Specker C, Heilinghaus A: Rituximab as a treatment option for refractory endogenous anterior uveitis. Ophthalmic Res 2007, 39:184-186.
48. Breedveld FC, Emery P, Keystone E, et al.: Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149-155.
49. Smith JR, Levinson RD, Holland GN, et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Care Res 2001, 45:252-257.
50. Hernandez-Illas M, Tozman E, Fulcher SFA, et al.: Recombinant human tumor necrosis factor receptor Fc fusion protein (etanercept): experience as a therapy for sight-threatening scleritis and sterile corneal ulceration. Eye Contact Lens 2004, 30:2-5.
51. Murphy CC, Ayliffe WH, Booth A, et al.: Tumor necrosis factor blockade with infliximab for refractory uveitis and scleritis. Ophthalmology 2004, 111:352-356.
52. Galor A, Perez VL, Hammel JP, Lowder CY: Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006, 113:2317-2323.
53. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005, 352:351-361.
54. Cheung CM, Murray PI, Savage CO: Successful treatment of Wegener's granulomatosis associated scleritis with rituximab. Br J Ophthalmol 2005, 89:1542.
55. Ahmadi-Simab K, Lamprecht P, Nolle B, et al.: Successful treatment of refractory anterior scleritis in primary Sjögren's syndrome with rituximab. Ann Rheum Dis 2005, 64:1087.
56. Paridaens D, van den Bosch WA, van der Loos TL, et al.: The effect of etanercept on Graves' ophthalmopathy: A pilot study. Eye 2005, 19:1286-1289.
57. DurranA OM, Reuser TQ, Murray PI: Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005, 24:117-119.
58. Garrity JA, Coleman AW, Matteson EL, et al.: Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am J Ophthalmol 2004, 138:925-930.
59. Adams AB, Kazim M, Lehman TJA: Treatment of orbital myositis with adalimumab (Humira). J Rheumatol 2005, 32:374-375.
60. Salvi M, Vannucchi G, Campi I, et al.: Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: An open study. Eur J Endocrinol 2007, 156:33-40.